Overview

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Status:
Withdrawn
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, two-stage, multi-arm Phase 1 study designed to evaluate the safety and preliminary efficacy of combining niraparib with four standard chemotherapy regimens used to treat TNBC.
Phase:
Phase 1
Details
Lead Sponsor:
Antoinette Tan, MD
Collaborator:
Tesaro, Inc.
Treatments:
Carboplatin
Cyclophosphamide
Doxorubicin
Niraparib
Paclitaxel